When vision loss strikes without warning, it’s often not bacteria—but fungi—lurking behind the damage. Fungal eye infections are far more common in South and Southeast Asia than in other regions, silently threatening millions. Yet despite their devastating potential, fungal endophthalmitis remains one of the most misunderstood and inconsistently managed eye diseases. Why? Because it rarely occurs, presents in confusing ways, and lacks large-scale studies to guide doctors. The result? Misdiagnoses, delayed treatments, and, too often, permanent blindness. And here’s where it gets even tougher—rising antifungal resistance and the absence of global testing standards make finding clear answers more urgent than ever.
Recognizing this critical gap, an international team has stepped up. The Asia-Pacific Vitreo-Retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII) have come together to publish the first-ever regional consensus on managing fungal endophthalmitis, detailed in Eye and Vision (DOI: 10.1186/s40662-025-00456-y, October 2025). This landmark publication contains 20 expert-driven statements crafted by 24 specialists from 12 countries, addressing key controversies head-on—like when to diagnose, how to treat, and whether corticosteroids still have a place in care.
Led by Professors Taraprasad Das and Dennis S. C. Lam, the project combined decades of clinical data and real-world experience into a powerful guideline structured around five pillars: disease characteristics, diagnosis, underlying biology, treatment approaches, and future directions. The group reached critical agreements along the way. They noted, for instance, that fungal infections often appear more slowly than bacterial ones, with Aspergillus, Candida, and Fusarium leading the charge. Those with weakened immune systems face the highest risk. Early vitrectomy—a surgical procedure to remove infected eye fluid—was strongly recommended to decrease fungal load and improve drug delivery. For medication strategies, experts endorsed combining intravitreal, systemic, and topical antifungals to attack infection from multiple fronts.
Modern technologies are changing the game, too. State-of-the-art molecular tools like polymerase chain reaction (PCR), next-generation sequencing (NGS), and MALDI-TOF mass spectrometry can detect fungi when traditional cultures fail. But controversy arises around corticosteroids: only a quarter of experts were willing to support intravitreal dexamethasone, citing fears that immune suppression could do more harm than good. This remains one of the most debated points—should steroids ever be used when battling a sight-threatening fungal infection?
Looking ahead, the new guidelines champion antifungal stewardship and advanced laboratory biomarkers like 1,3 β-D-glucan and galactomannan for faster and more accurate detection. They also highlight how newer drugs—like olorofim and terbinafine—could become crucial allies against resistant strains. These measures are designed not just to guide current practice but to prepare medicine for an evolving microbial battlefield.
Fungal endophthalmitis often goes unnoticed until it’s too late, but its outcomes can be catastrophic. By combining wisdom from across the Asia-Pacific region, these guidelines bridge a long-standing gap between research and real-world care. The recommendations give ophthalmologists a clear, structured path: detect early, target treatment precisely, and operate cautiously—because every hour saved could mean the difference between vision and blindness.
In many ways, this consensus marks a turning point not only for Asia-Pacific clinicians but for practitioners worldwide, especially in regions with fewer medical resources. Standardized definitions and treatment protocols will help doctors respond faster, more confidently, and more effectively. Incorporating molecular diagnostics and responsible antifungal use could also slow the spread of resistance, protecting future generations. And beyond the clinic, the report calls for an international watch on new pathogens like Candida auris, urging countries to share data and collaborate on surveillance.
These unified recommendations don’t just outline today’s best practices—they lay the foundation for tomorrow’s breakthroughs in fungal eye care, opening the door for multicenter trials, data sharing, and better patient outcomes. But here’s the question worth asking: will ophthalmologists globally adopt these guidelines, or will fragmented practices continue to cost countless patients their sight? What’s your take—should corticosteroids ever have a place in treating such infections? Share your thoughts and experiences in the comments below.
